crisaborole eucrisa - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 563

<< First< Prev

Page of 29

Next >Last >>

Showing results for crisaborole eucrisa. Your search for crisaborole；Eucrisa retrieved no results.

Select item 92923991.

A phase 2b, randomized, double‐blind, multicenter, vehicle‐controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild‐to‐moderate atopic dermatitis

Kayo Fujita, Michio Yagi, Shinichi Moriwaki, Mizuki Yoshida, Daniela Graham

J Dermatol. 2021 Nov; 48(11): 1640–1651. Published online 2021 Aug 26. doi: 10.1111/1346-8138.16120

PMCID:: PMC9292399

Abstract Article PDF–1.7M

Select item 67649312.

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups

Valerie D. Callender, Andrew F. Alexis, Linda F. Stein Gold, Mark G. Lebwohl, Amy S. Paller, Seemal R. Desai, Huaming Tan, William C. Ports, Michael A. Zielinski, Anna M. Tallman

Am J Clin Dermatol. 2019; 20(5): 711–723. Published online 2019 Jul 1. doi: 10.1007/s40257-019-00450-w

PMCID:: PMC6764931

Abstract Article PDF–1016K

Select item 71250593.

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

Joel Schlessinger, Julie S. Shepard, Richard Gower, John C. Su, Charles Lynde, Amy Cha, William C. Ports, Vivek Purohit, Liza Takiya, John L. Werth, Chuanbo Zang, Bonnie Vlahos, on behalf of the CARE 1 Investigators

Am J Clin Dermatol. 2020; 21(2): 275–284. Published online 2020 Mar 24. doi: 10.1007/s40257-020-00510-6

PMCID:: PMC7125059

Abstract Article PDF–1.1M

Select item 89408114.

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years

Thomas A. Luger, Adelaide A. Hebert, Andrea L. Zaenglein, Jonathan I. Silverberg, Huaming Tan, William C. Ports, Michael A. Zielinski

Paediatr Drugs. 2022; 24(2): 175–183. Published online 2022 Mar 16. doi: 10.1007/s40272-021-00490-y

PMCID:: PMC8940811

Abstract Article PDF–666K

Select item 77568825.

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis

Lawrence F. Eichenfield, Gil Yosipovitch, Linda F. Stein Gold, Mizuho Kalabis, Chuanbo Zang, Bonnie Vlahos, Paul Sanders, Daniela E. Myers, Andrew G. Bushmakin, Joseph C. Cappelleri, Melissa Olivadoti, Amy S. Paller

Pediatr Dermatol. 2020 Nov-Dec; 37(6): 1030–1037. Published online 2020 Sep 27. doi: 10.1111/pde.14328

PMCID:: PMC7756882

Abstract Article PDF–1.3M

Select item 75404236.

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis

Vivek Purohit, Steve Riley, Huaming Tan, William C. Ports

J Clin Pharmacol. 2020 Oct; 60(10): 1344–1354. Published online 2020 May 20. doi: 10.1002/jcph.1624

PMCID:: PMC7540423

Abstract Article PDF–389K

Select item 91750457.

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area

Jonathan I. SILVERBERG, Anna M. TALLMAN, William C. PORTS, Robert A. GERBER, Huaming TAN, Michael A. ZIELINSKI

Acta Derm Venereol. 2020; 100(13): 5744. Published online 2020 Jun 11. doi: 10.2340/00015555-3489

PMCID:: PMC9175045

Abstract Article PDF–1.5M

Select item 50847618.

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study

Lee T. Zane, Leon Kircik, Robert Call, Eduardo Tschen, Zoe Diana Draelos, Sanjay Chanda, Merrie Van Syoc, Adelaide A. Hebert

Pediatr Dermatol. 2016 Jul-Aug; 33(4): 380–387. Published online 2016 May 18. doi: 10.1111/pde.12872

PMCID:: PMC5084761

Abstract Article PDF–234K

Select item 50454899.

Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers

Lee T. Zane, Matilda H. Hughes, Sepehr Shakib

Am J Clin Dermatol. 2016; 17(5): 519–526. Published online 2016 Jun 22. doi: 10.1007/s40257-016-0204-6

PMCID:: PMC5045489

Abstract Article PDF–660K

Select item 650729510.

Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis

Huan Yang, Ji Wang, Xin Zhang, Yan Zhang, Zi-li Qin, Hua Wang, Xiao-yan Luo

JAMA Dermatol. 2019 May; 155(5): 585–593. Published online 2019 Mar 27. doi: 10.1001/jamadermatol.2019.0008

Correction in:: JAMA Dermatol. 2019 Jul; 155(7): 865.

PMCID:: PMC6507295

Abstract Article

Select item 748008411.

Management of Atopic Dermatitis in Children Younger Than Two Years of Age by Community Pediatricians: A Survey and Chart Review

Anna B. Fishbein, Noor Hamideh, Jennifer Lor, Sharon Zhao, Lacey Kruse, Maryann Mason, Adolfo Ariza, Liliana Bolanos, Jonathan Necheles, Bennett Kaye

J Pediatr. Author manuscript; available in PMC 2020 Sep 9.

Published in final edited form as: J Pediatr. 2020 Jun; 221: 138–144.e3. Published online 2020 Mar 11. doi: 10.1016/j.jpeds.2020.02.015

PMCID:: PMC7480084

Abstract Article PDF–489K

Select item 1006683012.

Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection

Christine Youn, Dustin A. Dikeman, Evelyn Chang, Haiyun Liu, Sabrina J. Nolan, Martin P. Alphonse, Daniel P. Joyce, Qi Liu, James Meixiong, Xinzhong Dong, Lloyd S. Miller, Nathan K. Archer

Exp Dermatol. Author manuscript; available in PMC 2024 Apr 1.

Published in final edited form as: Exp Dermatol. 2023 Apr; 32(4): 425–435. Published online 2022 Dec 19. doi: 10.1111/exd.14722

PMCID:: PMC10066830

Abstract Article PDF–1.5M

Select item 621466813.

Is there still a role for conventional topical atopic dermatitis treatments in the biologic era?

K. Abuabara, C. Flohr

Br J Dermatol. Author manuscript; available in PMC 2019 Mar 1.

Published in final edited form as: Br J Dermatol. 2018 Mar; 178(3): 583–584. doi: 10.1111/bjd.16316

PMCID:: PMC6214668

Article PDF–34K

Select item 660055614.

Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis

Lena McDowell, Bernie Olin

J Pharm Technol. 2019 Aug; 35(4): 172–178. Published online 2019 Apr 22. doi: 10.1177/8755122519844507

PMCID:: PMC6600556

Abstract Article PDF–370K

Select item 1105295615.

Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis

Lawrence F. Eichenfield, Linda F. Stein Gold, Charles Lynde, Lyn Guenther, Shoshana Greenberger, Chia-Yu Chu, Zara Ghodsi, Bonnie Vlahos, Paul Sanders, Amy Cha, Juliana M. Canosa

Dermatol Ther (Heidelb) 2024 Apr; 14(4): 875–892. Published online 2024 Mar 28. doi: 10.1007/s13555-024-01129-9

PMCID:: PMC11052956

Abstract Article PDF–957K

Select item 797832316.

Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation

Zih-Chan Lin, Tsong-Long Hwang, Tse-Hung Huang, Kohei Tahara, Jiří Trousil, Jia-You Fang

Theranostics. 2021; 11(10): 4567–4584. Published online 2021 Mar 4. doi: 10.7150/thno.56995

PMCID:: PMC7978323

Abstract Article PDF–4.1M

Select item 1018462617.

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study

Lawrence F. Eichenfield, Richard G. Gower, JinHua Xu, Maryam S. Alam, John C. Su, Daniela E. Myers, Paul Sanders, Bonnie Vlahos, Chuanbo Zang, Jar Lan, John Werth

Am J Clin Dermatol. 2023; 24(4): 623–635. Published online 2023 May 15. doi: 10.1007/s40257-023-00780-w

PMCID:: PMC10184626

Abstract Article PDF–1.9M

Select item 735545318.

In Vitro Skin Retention of Crisaborole after Topical Application

Adriana Fantini, Anna Demurtas, Sara Nicoli, Cristina Padula, Silvia Pescina, Patrizia Santi

Pharmaceutics. 2020 Jun; 12(6): 491. Published online 2020 May 28. doi: 10.3390/pharmaceutics12060491

PMCID:: PMC7355453

Abstract Article PDF–1.6M

Select item 775627819.

A phase I, randomized, double‐blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF‐06763809 in participants with mild‐to‐moderate plaque psoriasis

G. Berstein, Y. Zhang, Z. Berger, E. Kieras, G. Li, A. Samuel, T. Yeoh, H. Dowty, K. Beaumont, W. Wigger‐Alberti, Y. von Mackensen, U. Kroencke, R. Hamscho, S. Garcet, J. G. Krueger, C. Banfield, B. Oemar

Clin Exp Dermatol. 2021 Jan; 46(1): 122–129. Published online 2020 Sep 14. doi: 10.1111/ced.14412